New malaria vaccine shows 75% protection in large trial

A next-generation malaria vaccine has shown 75% efficacy in a large phase 3 trial involving children in sub-Saharan Africa, according to results published in The Lancet.

The findings mark a potentially important step in efforts to reduce one of the world’s deadliest infectious diseases, which continues to hit children hardest across much of Africa. Researchers said the vaccine’s performance in the trial was strong enough to raise hopes for broader public-health impact if it is approved and scaled up.

Malaria remains a major cause of illness and death in many low-income countries, despite years of prevention campaigns, bed nets and treatment programs. A vaccine with higher effectiveness could help close a persistent gap in protection, especially in areas where access to healthcare is limited.

While the results are encouraging, experts typically caution that trial success does not automatically translate into real-world impact. Wider deployment, cost, manufacturing capacity and ongoing monitoring will determine how much difference the vaccine can make in the fight against malaria.